- Home
- TNGX vs ATYR Comparison
TNGX vs ATYR Comparison
Compare TNGX & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- ATYR
- Stock Information
- Founded
- TNGX 2014
- ATYR 2005
- Country
- TNGX United States
- ATYR United States
- Employees
- TNGX N/A
- ATYR N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TNGX Health Care
- ATYR Health Care
- Exchange
- TNGX Nasdaq
- ATYR Nasdaq
- Market Cap
- TNGX 317.4M
- ATYR 330.7M
- IPO Year
- TNGX N/A
- ATYR 2015
- Fundamental
- Price
- TNGX $1.95
- ATYR $3.97
- Analyst Decision
- TNGX Strong Buy
- ATYR Strong Buy
- Analyst Count
- TNGX 7
- ATYR 6
- Target Price
- TNGX $12.33
- ATYR $18.60
- AVG Volume (30 Days)
- TNGX 809.1K
- ATYR 2.0M
- Earning Date
- TNGX 05-07-2025
- ATYR 03-13-2025
- Dividend Yield
- TNGX N/A
- ATYR N/A
- EPS Growth
- TNGX N/A
- ATYR N/A
- EPS
- TNGX N/A
- ATYR N/A
- Revenue
- TNGX $42,069,000.00
- ATYR $235,000.00
- Revenue This Year
- TNGX N/A
- ATYR $1,387.23
- Revenue Next Year
- TNGX N/A
- ATYR $873.22
- P/E Ratio
- TNGX N/A
- ATYR N/A
- Revenue Growth
- TNGX 15.17
- ATYR N/A
- 52 Week Low
- TNGX $1.72
- ATYR $1.42
- 52 Week High
- TNGX $12.02
- ATYR $4.66
- Technical
- Relative Strength Index (RSI)
- TNGX 37.66
- ATYR 56.81
- Support Level
- TNGX $1.80
- ATYR $2.98
- Resistance Level
- TNGX $2.01
- ATYR $3.73
- Average True Range (ATR)
- TNGX 0.21
- ATYR 0.40
- MACD
- TNGX 0.01
- ATYR 0.04
- Stochastic Oscillator
- TNGX 31.94
- ATYR 80.32
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.